Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...
Zacks.com on MSN2mon
Blueprint Stock Soars 18% on Encouraging 2025 Growth StrategyImage Source: Zacks Investment Research Blueprint is conducting an early-stage ... In three months, CytomX Therapeutics’ ...
Wolfe Research initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on ...
Short interest in Blueprint Medicines Corp (NASDAQ ... short interest to close out their positions without sending the stock sharply higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback